



**HAL**  
open science

# The Dynamic Effect of Direct-acting Antiviral Treatments on the Risk of Hepatocellular Carcinoma in Patients with Cirrhosis and Chronic Hepatitis C

Clovis Lusivika-Nzinga, H el ene Fontaine, C eline Dorival, M elanie Simony,  
Stanislas Pol, Fabrice Carrat

► **To cite this version:**

Clovis Lusivika-Nzinga, H el ene Fontaine, C eline Dorival, M elanie Simony, Stanislas Pol, et al.. The Dynamic Effect of Direct-acting Antiviral Treatments on the Risk of Hepatocellular Carcinoma in Patients with Cirrhosis and Chronic Hepatitis C. *Journal of Viral Hepatitis*, 2019, 26 (12), pp.1489–1492. 10.1111/jvh.13186 . hal-03703999

**HAL Id: hal-03703999**

**<https://hal.sorbonne-universite.fr/hal-03703999>**

Submitted on 24 Jun 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin ee au d ep ot et  a la diffusion de documents scientifiques de niveau recherche, publi es ou non,  emanant des  tablissements d'enseignement et de recherche fran ais ou  trangers, des laboratoires publics ou priv es.

1     **The dynamic effect of direct-acting antiviral treatments on the risk of**  
2             **hepatocellular carcinoma in patients with cirrhosis and chronic**  
3                     **hepatitis C.**

4  
5     **Running title:** Effect of DAAs on hepatocellular carcinoma.

6  
7     Clovis Lusivika-Nzinga<sup>a</sup>, Hélène Fontaine<sup>b</sup>, Celine Dorival <sup>a</sup>, Mélanie Simony<sup>c</sup>, Stanislas  
8     Pol<sup>b,d</sup>, Fabrice Carrat<sup>a,e</sup> , for the ANRS/AFEF Hepather study group.

9  
10    (a) Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de  
11    Santé Publique, Paris, France.

12    (b) Assistance Publique – Hôpitaux de Paris, Hôpital Cochin, Unité  
13    d'Hépatologie, Paris France.

14    (c) ANRS (France Recherche Nord&sud Sida-vih Hépatites), Unit for Basic and  
15    Clinical Research on Viral Hepatitis, Paris, France.

16    (d) Université Paris Descartes, INSERM U-123 et USM20, Institut Pasteur, Paris,  
17    France.

18    (e) Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Unité de Santé  
19    Publique, Paris, France.

20  
21  
22  
23     **Corresponding author.**

24     Fabrice CARRAT

25     Institut Pierre Louis Epidémiologie et Santé Publique, UMRS-1136

26     Faculté de médecine Sorbonne Université, Site Saint-Antoine

27     27 Rue Chaligny

28     75012, Paris, France

29     Phone : +33 1 7197 0110

30     E-mail : [fabrice.carrat@iplesp.upmc.fr](mailto:fabrice.carrat@iplesp.upmc.fr)

31  
32     **Acknowledgements.**

33  
34     We thank participants and participating clinicians at each study site; and Dale Roche-Lebrec

35     for help in editing the report. This study received funding from INSERM-ANRS (France

1 REcherche Nord&sud Sida-vih Hepatites), ANR (Agence Nationale de la Recherche), DGS  
2 (Direction Générale de la Santé) and MSD, Janssen, Gilead, Abbvie, BMS, Roche.

3  
4

5 **Conflict of interests.**

6  
7 Clovis Lusivika-Nzinga has nothing to disclose.

8

9 Hélène Fontaine reports personal fees and invitations for medical meeting from Gilead,  
10 Abbvie, BMS, MSD, Janssen, MSD outside this work.

11

12 Céline Dorival has nothing to disclose.

13

14 Mélanie Simony has nothing to disclose.

15

16 Stanislas Pol received consulting and lecturing fees from Bristol-Myers Squibb, Janssen,  
17 Gilead, Roche, Boehringer Ingelheim, MSD and Abbvie, and grants from Bristol-Myers  
18 Squibb, Gilead and MSD.

19

20 Fabrice Carrat reports grants from INSERM-ANRS, during the conduct of the study; personal  
21 fees from Imaxio, outside the submitted work.

22

23

24 **Author contribution.**

25 **CLN, HF, CD, MS, SP and FC** have made substantial contributions to study conception and  
26 design. **HF, CD and SP** have made substantial contributions to acquisition of data. **CLN and**  
27 **FC** have been involved in drafting the manuscript and made substantial contributions to

1 statistical analysis of data. **HF, CD, MS and SP** have been involved in revising the manuscript  
2 critically for important intellectual content. All authors read and gave final approval of the  
3 version to be published and agreed to be accountable for all aspects of the work.

## 4 5 **Abstract**

6  
7  
8 There is still some controversy over a potentially increased short-term risk of developing  
9 hepatocellular carcinoma (HCC) after the initiation of direct-acting antiviral (DAA) therapy,  
10 even though a decreased long-term risk of HCC has been reported following a sustained  
11 virological response in patients with chronic hepatitis C virus (HCV) infection. We  
12 characterized the time-varying effect of DAAs on the risk of the occurrence of HCC in patients  
13 with cirrhosis and HCV infection. We analyzed patients with cirrhosis and chronic HCV  
14 infection from the ANRS CO22 HEPATHER cohort study. We excluded patients with active  
15 HBV coinfection, liver transplantation or a past history of HCC. We used a flexible weighted  
16 effect cumulative exposure Cox model to characterize the time-varying effect of DAAs on the  
17 risk of HCC. A total of 3595 patients, mean age 59.3 years old, 65% men, were eligible for the  
18 study. Median follow-up was 36.8 months (IQR 24.6-47.1). DAAs were started during follow-  
19 up in 3292 patients. Three hundred and fifty-six HCCs were reported (275 treated, 81  
20 untreated). Overall, a constant decrease in the risk of occurrence of HCC (vs untreated) was  
21 found from the start of treatment. Results were similar in patients without a history of  
22 decompensated cirrhosis (DC). Analysis of patients with a past history of DC showed a non-  
23 significant increase in the occurrence of HCC over the first 6 months, while the HR was  
24 significantly decreased at 14 months. These findings support the urgent initiation of DAAs in  
25 all patients.

26  
27

1 **Keywords:** Hepatocellular carcinoma, Hepatitis C virus, Direct-acting antiviral agents,  
2 Weighted cumulative exposure model, time-varying effect.

3 **Word count:** 1500

4

5 This manuscript has not been published.

6

7

1 **1. Introduction**

2 Since 2014, the use of direct-acting antiviral (DAA) treatment has completely revolutionized  
3 the treatment of patients with chronic HCV infection. A combination of 2-3 DAAs results in a  
4 sustained virological response (SVR) in more than 95% of treated patients. This high SVR rate  
5 has raised hopes for a significant reduction in the incidence of HCC, like that reported with  
6 interferon-based regimens [1]. However, the dynamic impact of DAAs on the risk of HCC in  
7 patients with chronic HCV and how the risk of HCC varies over time in patients who receive  
8 DAAs compared to those who do not, remain unclear. Despite the overall decrease in the risk  
9 of *de novo* HCC reported in the 3 years following treatment, there has been some controversy  
10 concerning the increased short term risk of HCC following the initiation of DAAs, in particular  
11 in patients with cirrhosis [2, 3]. However, the use of a single measure, the average fixed hazard  
12 ratio (HR), during follow-up may not reflect the potentially complex time-dependent  
13 relationship between exposure to DAAs and the risk of HCC. Our objective was to characterize  
14 the effect of DAAs on the risk of the occurrence of HCC over time in patients with cirrhosis  
15 and HCV infection.

16  
17  
18  
19  
20  
21  
22  
23  
24

## 1 2. Methods

2 Patients were selected from the ANRS CO22 HEPATHER cohort study [4] and enrolled from  
3 August 6, 2012 to December 31, 2015. All patients with cirrhosis at entry in the cohort were  
4 selected and patients with active HBV coinfection defined by detectable HBsAg (n=35), liver  
5 transplantation (n=107) or a past history of HCC (n=442) were excluded.

6 Cirrhosis was based on a platelet count  $< 150,000/\mu\text{L}$  or a prothrombin time  $< 70\%$  at entry in  
7 1772 patients. These criteria were validated in 757 patients who had also been evaluated for  
8 liver fibrosis, including 755 who had been classified with cirrhosis by other procedures (liver  
9 biopsy=45, fibroscan=682, fibrotest=332, fibrometer=46, hepascore=85, a patient could have  
10 several procedures). In other patients, cirrhosis was based on liver biopsy (n=110) or another  
11 non-invasive test (liver stiffness measurement (Fibroscan $\text{\textcircled{R}}$  $>12.5$  kPa) (n=594),  
12 Fibrotest $\text{\textcircled{R}}$  $>0.75$  (n=421), Fibrometer $\text{\textcircled{R}}$  $>0.98$  (n=184), or the Hepascore $>0.84$  (n=26) that was  
13 performed closest to the date of inclusion, but less than 1 year before and up to 3 months after  
14 inclusion. If a recent measurement of fibrosis was not available or in case of discrepancies  
15 between non-invasive fibrosis markers, we used the physician's assessment of cirrhosis at  
16 enrolment based on past assessments of liver fibrosis and the patient's history of liver-related  
17 comorbidities (n=488).

18 Patients were further categorized according to a history of decompensated cirrhosis (DC),  
19 defined as past episodes or the presence of ascites, variceal hemorrhage, encephalopathy,  
20 and/or jaundice at entry [5], and their sustained virological response (SVR) status. Follow-up  
21 included systematic visits (every 6 months for patients with cirrhosis) and spontaneous reports  
22 of particular events including the diagnosis of *de novo* HCC on specific data forms. Survival  
23 time was calculated as the time between inclusion in the study or the initiation of DAAs and  
24 the diagnosis of HCC or February 1, 2019, whichever occurred first. To take into account  
25 competing events, HCC-free survival was censored in case of death or liver transplantation

1 during follow-up. Participants who initiated DAAs were considered to be exposed until the end  
2 of follow-up. To characterize the time-varying effect of DAAs on the risk of HCC, we used a  
3 flexible weighted cumulative exposure (WCE) Cox model with DAAs exposure modeled as a  
4 weighted sum of the months following the initiation of treatment [6]. The weighted function  
5 was estimated using regression with cubic B-splines, allowing the HR to increase or decrease  
6 smoothly over time from the beginning of treatment. For comparison purposes, we also  
7 computed the fixed HR using a conventional multivariable Cox proportional hazards model.  
8 We estimated the time-varying and fixed hazard ratio according to SVR status (yes or no  
9 compared to not exposed to DAAs), with SVR status evaluated from 3 months after the last  
10 day of DAAs [4]). Exposure to DAAs was also entered as a time-dependent covariate and  
11 adjusted for age, gender, geographic origin, HCV genotype, a history of decompensated  
12 cirrhosis (DC), albuminemia, platelet count and alfa fetoprotein as fixed covariates. All  
13 calculations were performed using SAS v9.4 software (SAS Institute Inc, Cary, NC, USA).

### 14 **3. Results**


15 A total of 3,595 patients (3043 and 552 without and with a history of DC, respectively), mean  
16 age 59.3 years old, 65% men, were eligible for the study. DAA treatment was started in 3292  
17 (92%) patients during follow-up while 303 (8%) patients remained untreated at the end of the  
18 follow-up, representing 8755 Person-Years (PY) exposed and 1718 PY unexposed to DAAs.  
19 The median follow-up was 36.8 months (IQR 24.6 – 47.1). SVR status was available in 3045  
20 (92%) treated patients, 2613 (92%) and 432 (93%) in patients without and with a history of  
21 DC, respectively. A SVR was achieved in 2779 (91%), 2406 (92%) and 373 (86%) patients,  
22 respectively. Three hundred and fifty-six HCCs (3.4/100 PY) were reported including 275  
23 (3.1/100 PY) in patients exposed to DAAs and 81 (4.7/100 PY) in unexposed patients, 263  
24 (2.9/100 PY) and 93 (6.6/100 PY) in patients without and with a history of DC, 192 (2.3/100  
25 PY) and 67 (9.3/100 PY) in patients exposed to DAAs with or without a SVR, 167 (2.2/100



1 PY) and 52 (8.6/100 PY) in patients without a history of DC with or without a SVR and 54  
2 (5.0/100 PY) and 20 (16/100 PY) in patients with a history of DC with or without a SVR,  
3 respectively. Two hundred and eighty-four deaths and 71 liver transplantations were reported.  
4 Time-varying and fixed HR are shown in Figure 1. Overall, a constant decrease in the risk of  
5 occurrence of HCC (vs untreated) was found from the start of treatment. The HR was  
6 significant at 9 months (0.65 (95% CI 0.43; 0.97)) and reached a minimum of 0.47 (95% CI  
7 0.27; 0.81) at 30 months (Fig 1a.). Results were similar when the analysis was limited to 3043  
8 patients without a history of DC (fig 1b.). An analysis of 552 patients with a past history of DC  
9 showed a slight non-significant increase in the occurrence of HCC in treated versus untreated  
10 patients over the first 6 months, while the HR was significantly decreased at 14 months (0.39  
11 (95% CI 0.18; 0.85)) to reach a minimum at 22 months (0.18 (95% CI 0.07; 0.47)) (Fig 1c.).  
12 Similar results were found when analyses were performed in patients who achieved a SVR (Fig  
13 1: d-f). A progressive increase in the risk of occurrence of HCC (vs untreated) was found in all  
14 subgroups of patients who did not achieve a SVR (Fig 1: d-f). Fixed-HR estimates indicated a  
15 significant association between exposure to DAAs and a decreased risk of HCC, except in  
16 patients with a past history of DC. This confirmed the increased risk of HCC in patients who  
17 did not achieve a SVR.

18

19



1

2 **Figure 1. Time-varying effects (solid curves) and 95% point-wise confidence bounds (dotted**  
 3 **curves) of DAAs on HCC. Upper panel shows time-varying effects in all patients who received**  
 4 **DAAs (a-c) compared to those who did not receive DAAs. Lower panel (d-f) shows time-varying**  
 5 **effects in patients who achieved (red curve) and those who did not achieve a SVR (blue curve)**  
 6 **compared to patients who did not receive DAAs.**

7

8

9

10

11

12

13

14

15

16

17

18

## 1 **4. Discussion**

2 This study shows that the risk of the occurrence of HCC in patients with cirrhosis and chronic  
3 HCV infection progressively decreases after the initiation of DAAs compared to untreated  
4 patients. The present report updates a previous study [4] while highlighting that this association  
5 varies over time.

6 The main strengths of our study are the prospective design, the large number of patients with  
7 cirrhosis including patients with a history of DC, the 3-year median duration of follow-up, and  
8 especially, the comparison of treated and untreated patients with multivariate adjustment for  
9 the risk factors of HCC. The main limitation of this study was reverse causality. In particular,  
10 if patients with more advanced liver disease and a higher risk of HCC had a lower probability  
11 of starting treatment this could potentially explain the early negative association between the  
12 development of HCC and treatment exposure in the first year. However, the HR between  
13 treated and untreated patients continually decreased, except in the subset of patients with DC.  
14 This suggests that DAAs have a potentially rapid impact on the risk of HCC that accumulates  
15 over time in patients without DC. In patients with DC, the non-significant short-term increase  
16 risk of HCC over the first 6 months warrants further study, but appears to be associated with  
17 the lack of SVR in this subgroup of patients. Potentially missed HCC diagnoses are another  
18 limitation if some patients have been screened less regularly than recommended. However, the  
19 average number of follow-up visits and ultrasound examinations were higher in patients after  
20 than before treatment or in patients who remained untreated (11.0 and 2.6 vs 2.2 and 0.8,  
21  $P < 0.0001$  and  $P < 0.0001$ , respectively). Therefore, any screening bias would reinforce our  
22 conclusion.

23 Also, the rates of HCC in DAA treated patients in our study are consistent with those reported  
24 in therapeutic cohort studies in patients with cirrhosis [1-3] as well as other comparative studies  
25 suggesting that DAAs significantly reduce the short term risk of HCC [7].

1 Altogether, our findings support the urgent initiation of DAAs in all patients with chronic HCV  
2 and cirrhosis. The short-term influence of DAAs on HCC in patients with a history of  
3 decompensated cirrhosis must still be clarified.

4

## 5 **References**

- 6 1. Nahon, P., et al., *Eradication of Hepatitis C Virus Infection in Patients*  
7 *With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.*  
8 *Gastroenterology*, 2017. **152**(1):142-156.e2.
- 9 2. Roche, B., et al., *The impact of treatment of hepatitis C with DAAs on the*  
10 *occurrence of HCC.* *Liver Int*, 2018. **38 Suppl 1**:139-145.
- 11 3. Singh, S., A. Nautiyal, and Y.K. Loke, *Oral direct-acting antivirals and*  
12 *the incidence or recurrence of hepatocellular carcinoma: a systematic*  
13 *review and meta-analysis.* *Frontline Gastroenterol*, 2018. **9**(4):262-270.
- 14 4. Carrat, F., et al., *Clinical outcomes in patients with chronic hepatitis C*  
15 *after direct-acting antiviral treatment: a prospective cohort study.*  
16 *Lancet*, 2019. **393**(10179):1453-1464.
- 17 5. Garcia-Tsao, G., et al., *Now there are many (stages) where before there*  
18 *was one: In search of a pathophysiological classification of cirrhosis.*  
19 *Hepatology*, 2010. **51**(4):1445-9.
- 20 6. Sylvestre, M.P. and M. Abrahamowicz, *Flexible modeling of the*  
21 *cumulative effects of time-dependent exposures on the hazard.* *Stat Med*,  
22 2009. **28**(27):3437-53.
- 23 7. Li, D.K., et al., *The short-term incidence of hepatocellular carcinoma is*  
24 *not increased after hepatitis C treatment with direct-acting antivirals: An*  
25 *ERCHIVES study.* *Hepatology*, 2018. **67**(6):2244-2253.
- 26